The role of the Interleukin 1 receptor-like 1 (ST2) and Interleukin-33 pathway in cardiovascular disease and cardiovascular risk assessment

Minerva Medica

Volumn 103, Issue 6, 2012, Pages 513-523

  Willems, S ^a   Hoefer, I ^a   Pasterkamp, G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Atherosclerosis; Biological markers; Cardiovascular disease

Indexed keywords

INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR LIKE 1; INTERLEUKIN 33; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC DISEASE; HEART FAILURE; HEART HYPERTROPHY; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART TRANSPLANTATION; HUMAN; NONHUMAN; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKINS; MICE; RECEPTORS, CELL SURFACE;

EID: 84875356421     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23:479-90. (Pubitemid 41587888)
2. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel "alarmin"? PLoS One 2008;3:e3331.
3. Choi Y, Park J, Kim J, Rho S, Park H, Kim Y et al. Nuclear IL-33 is a transcriptional regulator of NF-κB p65 and induces endothelial cell activation. Biochem Biophys Res Commun 2012;421:305-11.
4. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci 2007;104:282-7. (Pubitemid 46068023)
5. Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Küchler AM. Interleukin-33 - cytokine of dual function or novel alarmin? Trends Immunol 2009;30:227-33.
6. Sanada S, Hakuno D, Higgins L, Schreiter E, McKenzie AN, Lee R. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007;117:1538-49. (Pubitemid 46871338)
7. Kakkar R, Hei H, Dobner S, Lee RT. Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J Biol Chem 2012;287:6941-8.
8. Ohno T, Oboki K, Kajiwara N, Morii E, Aozasa K, Flavell R et al. Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J Immunol 2009;183:7890-7.
9. Hsu C-L, Neilsen C V, Bryce PJ. IL-33 Is Produced by Mast Cells and Regulates IgE-Dependent Inflammation. PLoS one 2010;5:e11944.
10. Talabot-Ayer D, Lamacchia C, Gabay C, Palmer G. Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem 2009;284:19420-6.
11. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A 2009;106:9021-6.
12. Lüthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 2009;31:84-98.
13. Ali S, Nguyen DQ, Falk W, Martin MU. Caspase 3 inactivates biologically active full length interleukin-33 as a classical cytokine but does not prohibit nuclear translocation. Biochem Biophys Res Commun 2010;391:1512-6.
14. Bergers G, Reikerstorfer A, Braselmann S, Graninger P, Busslinger M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J 1994;13:1176-88. (Pubitemid 24074724)
15. Tominaga SI, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, Komatsu N. Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7GM. Biochem Biophys Res Commun 1999;264:14-8. (Pubitemid 29500455)
16. Yanagisawa K, Naito Y, Kuroiwa K, Arai T, Furukawa Y, Tomizuka H et al. The expression of ST2 gene in helper T cells and the binding of ST2 protein to myeloma-derived RPMI8226 cells. J Biochem 1997;121:95-103. (Pubitemid 27068281)
17. Löhning M, Stroehmann A, Coyle AJ, Grogan JL, Lin S, Gutierrez-Ramos JC et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A 1998;95:6930-5. (Pubitemid 28278084)
18. Xu D, Chan W, Leung B, Huang F, Wheeler R, Piedrafita D et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 1998;187:787-94. (Pubitemid 28115194)
19. Moritz DR, Rodewald HR, Gheyselinck J, Klemenz R. The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J Immunol 1998;161:4866-74. (Pubitemid 28492065)
20. Coyle AJ, Lloyd C, Tian J, Nguyen T, Erikkson C, Wang L et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med 1999;190.895-902.
21. Kropf P, Herath S, Klemenz R, Müller I. Signaling through the T1/ST2 Molecule Is Not Necessary for Th2 Differentiation but Is Important for the Regulation of Type 1 Responses in Nonhealing Leishmania-major Infection. Infect Immun 2003;71:1961-71. (Pubitemid 36368729)
22. Meisel C, Bonhagen K, Löhning M, Coyle AJ, Gutierrez-Ramos JC, Radbruch A et al. Regulation and function of T1/ST2 expression on CD4+ T cells: induction of type 2 cytokine production by T1/ST2 cross-linking. J Immunol 2001;166:3143-50. (Pubitemid 33117311)
23. Komai-Koma M, Xu D, Li Y, McKenzie AN, McInnes IB, Liew FY. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 2007;37:2779-86. (Pubitemid 47578297)
24. Townsend MJ, Fallon PG, Matthews DJ, John HE, McKenzie A. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med 2000;191:1069-76.
25. Walzl G, Matthews S, Kendall S, Gutierrez-Ramos JC, Coyle AJ, Openshaw P et al. Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)-but not Th1-driven immunopathology. J exp Med 2001;193:785-92. (Pubitemid 32524528)
26. Louten J, Rankin AL, Li Y, Murphy EE, Beaumont M, Moon C et al. Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. Int Immunol 2011;23:307-15.
27. Miller AM, Liew FY. The IL-33/ST2 pathway - A new therapeutic target in cardiovascular disease. Pharmacol Ther 2011;131:179-86.
28. Hoshino K, Kashiwamura S, Kuribayashi K, Kodama T, Tsujimura T, Nakanishi K et al. The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J Exp Med 1999;190:1541-7.
29. Li H, Tago K, Io K, Kuroiwa K, Arai T, Iwahana H et al. The cloning and nucleotide sequence of human ST2L cDNA. Genomics 2000;67:284-90. (Pubitemid 30651029)
30. van 't Veer C, van den Pangaart PS, van Zoelen MA, de Kruif M, Birjmohun RS, Stroes ES et al. Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. J Immunol 2007;179:7110-20.
31. Wagenaar JF, Gasem MH, Goris MG, Leeflang M, Hartskeerl RA, van der Poll T et al. Soluble ST2 levels are associated with bleeding in patients with severe Leptospirosis. PLoS Negl Trop Dis 2009;3:e453.
32. Tominaga S. A putative protein of a growth-specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett 1989;258:301-4. (Pubitemid 20001074)
33. Houghton-Triviño N, Salgado DM, Rodríguez JA, Bosch I, Castellanos JE. Levels of soluble ST2 in serum associated with severity of dengue due to tumour necrosis factor alpha stimulation. J Gen Virol 2010;91:697-706.
34. Weinberg EO, Schimpo M, De Keulenaer GW, MacGillivray C, Tominaga S-I, Solomon SD et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocvtes and myocardial infarction. Circulation 2002;106:2961-6. (Pubitemid 35424749)
35. Zhao J, Chen Q, Li H, Myerburg M, Spannhake EW, Natarajan V et al. Lysophosphatidic acid increases soluble ST2 expression in mouse lung and human bronchial epithelial cells. Cell Signal 2012;24:77-85.
36. Zhang HF, Xie SL, Cheng YX, Mai JT, Wang JF, Zhu WL et al. Altered serum levels of IL-33 in patients with advanced systolic chronic heart failure: correlation with oxidative stress. J Transl Med 2012;10:120.
37. Bartunek J, Delrue L, Van Durme F, Muller O, Casselman F, De Wiest B et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol 2008;52:2166-74.
38. Zeyda M, Wernly B, Demyanets S, Kaun C, Hämmerle M, Hantusch B et al. Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue. Int J Obes (Lond) 2012 [Epub ahead of print].
39. Fousteris E, Melidonis A, Panoutsopoulos G, Tzirogiannis K, Foussas S, Theodosis-Georgilas A et al. Toll/interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction. Cardiovasc Diabetol 2011;10:101.
40. Rehman SU, Mueller T, Januzzi JL Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 2008;52:1458-65.
41. Broch K, Ueland T, Nymo SH, Kjekshus J, Hulthe J, Muntendam P et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. Eur J Heart Fail 2012;14:268-77.
42. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of Serum Soluble ST2 Receptor as a Novel Heart Failure Biomarker. Circulation 2003;107:721-6. (Pubitemid 36222600)
43. Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008;54:752-6. (Pubitemid 351573718)
44. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Amman EM et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004;109:2186-90. (Pubitemid 38625395)
45. Brunner M, Krenn C, Roth G, Moser B, Dworschak M, Jensen-Jarolim E et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med 2004;30:1468-73. (Pubitemid 38951733)
46. Szerafin T, Niederpold T, Mangold A, Hoetzenecker K, Hacker S, Roth G et al. Secretion of soluble ST2 - possible explanation for systemic immunosupression after heart surgery. Thorac Cardiovasc Surg 2009;57:25-9.
47. Szerafin T, Brunner M, Horvath A, Szentgyorgyi L, Moser B, Boltz-Nitulescu G et al. Soluble ST2 protein in cardiac surgery: a possible negative feedback loop to prevent uncontrolled inflammatory reactions. Clin Lab 2005;51:657-63. (Pubitemid 41763084)
48. Willems S, Sels JW, Flier S, Versteeg D, Buhre WF, de Kleijn DP et al. Temporal changes of soluble ST2 after cardiovascular interventions. Eur J Clin Invest 2012 [Epub ahead of print].
49. Santhanakrishnan R, Chong JP, Ng TP, Ling LH, Sim D, Leong KT et al. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 2012 [Epub ahead of print].
50. Dieplinger B, Gegenhuber A, Haltmayer M, Mueller T. Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart 2009;95:1508-13.
51. Brown AM, Wu AH, Clopton P, Robey JL, Hollander JE. ST2 in emergency department chest pain patients with potential acute coronary syndromes. Ann Emerg Med 2007;50:153-8.
52. Dhillon OS, Narayan HK, Khan SQ, Kelly D, Quinn PA, Squire IB et al. Pre-discharge risk stratification in unselected STEMI: Is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers? Int J Cardiol 2012 [Epub ahead of print].
53. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008;117:1936-44. (Pubitemid 351543469)
54. Pascual-Figal DA, Manzano-Fernández S, Boronat M, Casas T, Garrido IP, Bonaque JC et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011;13:718-25.
55. Manzano-Fernández S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 2011;107:259-67.
56. Boisot S, Beede J, Isakson S, Chiu A, Clopton P, Januzzi J et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail 2008;14:732-8.
57. Bayes-Genis A, de Antonio M, Galán A, Sanz H, Urrutia A, Cabanes R et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail 2012;14:32-8.
58. Bayes-Genis A, Pascual-Figal D, Januzzi JL, Maisel A, Casas T, Valdés Chávarri M et al. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure. Rev Esp Cardiol 2010;63:1171-8.
59. Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P et al. High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure. Circ Heart Fail 2011;4:180-7.
60. Zilinski JL, Shah R V, Gaggin HK, Gantzer ML, Wang TJ, Januzzi JL Jr. Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy. Crit Care 2012;16:R135.
61. Manzano-Fernández S, Januzzi JL, Pastor-Pérez FJ, Bonaque-González JC, Boronat-Garcia M, Pascual-Figal DA et al. Serial Monitoring of Soluble Interleukin Family Member ST2 in Patients with Acutely Decompensated Heart Failure. Cardiology 2012;122:158-66.
62. Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS et al. Role of ST2 in Non-ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial. Clin chem 2012;58:257-66.
63. Aldous SJ, Richards AM, Troughton R, Than M. ST2 Has Diagnostic and Prognostic Utility for All-Cause Mortality and Heart Failure in Patients Presenting to the Emergency Department With Chest Pain. J Cardiac Fail 2012;18:304-10.
64. Dieplinger B, Gegenhuber A, Kaar G, Poelz W, Haltmayer M, Mueller T. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin. Biochem 2010;43:714-9.
65. Martinez-Rumayor A, Camargo CA, Green SM, Baggish AL, O'Donoghue M, Januzzi JL. Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease. Am J Clin Pathol 2008;130:578-84.
66. Rehman SU, Martinez-Rumayor A, Mueller T, Januzzi JL Jr. Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Clin Chim Acta 2008;392:41-5.
67. Socrates T, DeFilippi C, Reichlin T, Twerenbold R, Breidhardt T, Noveanu M et al. Interleukin family member ST2 and mortality in acute dyspnoea. J Intern Med 2010;268:493-500.
68. Januzzi JL Jr, Rehman S, Mueller T, van Kimmenade RR, Lloyd-Jones DM. Importance of biomarkers for long-term mortality predection in acutely dyspneic patients. Clin Chem 2010;56:1814-21.
69. Januzzi JL Jr, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007;50:607-13. (Pubitemid 47199007)
70. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail 2009;2:311-9.
71. Daniels LB, Clopton P, Iqbal N, Tran K, Maisel AS. Association of ST2 levels with cardiac structure and function and mortality in outpatients. Am Heart J 2010;160:721-8.
72. Dieplinger B, Egger M, Koehler W, Firlinger F, Poelz W, Lenz K et al. Prognostic value of soluble ST2 in an unselected cohort of patients admitted to an intensive care unit - The Linz Intensive Care Unit (LICU) study. Clin Chem Acta 2012;413:587-93.
73. Wang TJ, Wollen KC, Larson MG, Coglianese E, McCabe EL, Cheng S et al. Prognostic Utility of Novel Biomarkers of Cardiovascular Stress:The Framingham Heart Study. Circulation 2012;126:1596-604.
74. Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007;282:26369-80. (Pubitemid 47443815)
75. Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009;2:684-91.
76. Turnquist HR, Zhao Z, Rosborough BR, Liu Q, Castellaneta A, Isse K et al. IL-33 expands suppressive CD11b+ Gr-1int and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol 2011;187:4598-610.
77. Tsapaki A, Zaravinos A, Apostolakis S, Voudris K, Vogiatzi K, Kochiadakis GE et al. Genetic variability of the distal promoter of the ST2 gene is associated with angiographic severity of coronary artery disease. J Thromb Trombolysis 2010;30:365-71.
78. Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008;205:339-46. (Pubitemid 351281600)
79. McLaren JE, Michael DR, Salter RC, Ashlin TG, Calder CJ, Miller AM et al. IL-33 reduces macrophage foam cell formation. J Immunol 2010;185:1222-9.
80. Miller AM, Asquith DL, Hueber AJ, Anderson LA, Holmes WM, McKenzie AN et al. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in Mice. Circ Res 2010;107:650-8.
81. Demyanets S, Konya V, Kastl SP, Kaun C, Rauscher S, Niessner A et al. Interleukin-33 Induces Expression of Adhesion Molecules and Inflammatory Activation in Human Endothelial Cells and in Human Atherosclerotic Plaques. Arterioscler Thromb Vasc Biol 2011;31:2080-9.
82. Zhu J, Carver W. Effects of interleukin-33 on cardiac fibroblast gene expression and activity. Cytokine 2012,58:368-79.
83. Marvie P, Lisbonne M, L'helgoualc'h A, Rauch M, Turlin B, Preisser L et al. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med 2010;14:1726-39.
84. Amatucci A, Novobrantseva T, Gilbride K, Brickelmaier M, Hochman P, Ibraghimov A. Recombinant ST2 boosts hepatic Th2 response in vivo. J Leukoc Biol 2007;82:124-32. (Pubitemid 47026424)
85. Volarevic V, Mitrovic M, Milovanovic M, Zelen I, Nikolic I, Mitrovic S et al. Protective Role of IL-33/ST2 Axis in Con A-Induced Hepatitis. J Hepatol 2012;56:26-33.
86. Sakai N, Van Sweringen HL, Quillin RC, Schuster R, Blanchard J, Burns JM et al. Interleukin-33 is hepatoprotective during liver ischemia/reperfusion in mice. Hepatology 2012;56:1468-78.
87. Masamune A, Watanabe T, Kikuta K, Satoh K, Kanno A, Shimosegawa T. Nuclear expression of interleukin-33 in pancreatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2010;299:G821-G832.
88. Rankin AL, Mumm JB, Murphy E, Turner S, Yu N, McClanahan TK et al. IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol 2010;184:1526-35.
89. Sweet M, Leung B, Kang D, Sogaard M, Schulz K, Trajkovic V et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol 2001;166.6633-9.
90. Yin H, Li XY, Yuan BH, Zhang BB, Hu SL, Gu HB et al. Adenovirus-mediated overexpression of soluble ST2 provides a protective effect on lipopolysaccharide-induced acute lung injury in mice. Clin Exp Immunol 2011;164:248-55.
91. Takezako N, Hayakawa M, Hayakawa H, Aoki S, Yanagisawa K, Endo H et al. ST2 suppresses IL-6 production via the inhibition of IkappaB degradation induced by the LPS signal in THP-1 cells. Biochem Biophys Res Commun 2006;341:425-32. (Pubitemid 43152122)
92. Nagata A, Takezako N, Tamemoto H, Ohto-Ozaki H, Ohta S, Tominaga S et al. Soluble ST2 protein inhibits LPS stimulation on monocyte-derived dendritic cells. Cell Mol Immunol 2012;9:399-409.
93. Brint EK, Xu D, Liu H, Dunne A, Mckenzie AN, O'Neill LA et al. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 2004;5:373-9. (Pubitemid 38500085)
94. Liu J, Buckley JM, Redmond HP, Wang JH. ST2 negatively regulates TLR2 signaling, but is not required for bacterial lipoprotein-induced tolerance. J Immunol 2010;184:5802-8.
95. Kumar S, Tzimas MN, Griswold DE, Young PR. Expression of ST2, an Interleukin-1 Receptor Homologue, Is Induced by Proinflammatory Stimuli. Biochem Biophys Res Commun 1997;235:474-8. (Pubitemid 27326503)
96. Tajima S, Oshikawa K, Tominaga S, Sugiyama Y. The Increase in Serum Soluble ST2 Protein Upon Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Chest 2003;124:1206-14. (Pubitemid 37290028)
97. Küchler AM, Pollheimer J, Balogh J, Sponheim J, Manley L, Sorensen DR et al. Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol 2008;173:1229-42.
98. Choi YS, Choi HJ, Min JK, Pyun BJ, Maeng YS, Park H et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 2009;114:3117-26.
99. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond) 2011;8:22.
100. Stolarski B, Kurowska-Stolarska M, Kewin P, Xu D, Liew FY. IL-33 Exacerbates Eosinophil-Mediated Airway Inflammation. J Immunol 2010;185:3472-80.
101. Yin H, Li X, Liu T, Yuan B, Zhang B, Hu S et al. Adenovirus-mediated delivery of soluble ST2 attenuates ovalbumin-induced allergic asthma in mice. Clin Exp Immunol 2012;170:1-9.
102. Kearley J, Buckland KF, Mathie SA, Lloyd CM. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med 2009;179:772-81.
103. Leung BP, Xu D, Culshaw S, McInnes IB, Liew FY. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol 2004;173:145-50. (Pubitemid 38797335)
104. Xu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A 2008;105:10913-8.
105. Xu D, Jiang HR, Li Y, Pushparaj PN, Kurowska-Stolarska M, Leung BP et al. IL-33 exacerbates autoantibody-induced arthritis. J Immunol 2010;184:2620-6.
106. Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum 2009;60:738-49.
107. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007;179:2551-5.
108. Ali S, Huber M, Kollewe C, Bischoff SC, Falk W, Martin MU. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci U S A 2007;104:18660-5. (Pubitemid 350210753)
109. Bulek K, Swaidani S, Qin J, Lu Y, Gulen MF, Herjan T et al. The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response. J Immunol 2009;182:2601-9.
110. Pascual-Figal DA, Ordoñez-Llanos J, Tornel PL, Vázquez R, Puig T, Valdés M et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol 2009;54:2174-9.
111. Eggers KM, Armstrong PW, Califf RM, Simoons ML, Venge P, Wallentin L et al. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am Heart J 2010;159:788-94.
112. Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol 2010;55:243-50.
113. Dhillon OS, Narayan HK, Quinn PA, Squire IB, Davies JE, Ng LL. Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: Comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP. Am Heart J 2011;161:1163-70.
114. Dworakowski R, Wendler O, Bhan A, Smith S, Pearson P, Alcock E et al. Successful transcatheter aortic valve implantation (TAVI) is associated with transient left ventricular dysfunction. Heart 2012;98:1641-6.